Immediate Impact
41 standout
Citing Papers
The present and future of bispecific antibodies for cancer therapy
2024 Standout
Multifunctional nanoparticle-mediated combining therapy for human diseases
2024 Standout
Works of Jon Beauchamp being referenced
Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia
2019
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Jon Beauchamp | 60 | 109 | 36 | 112 | 9 | 272 | |
| Hollie M. Reeves | 75 | 89 | 10 | 92 | 15 | 291 | |
| Tal Sapir | 28 | 76 | 34 | 142 | 10 | 322 | |
| Véronique Frémeaux-Bacchi | 8 | 79 | 10 | 107 | 6 | 261 | |
| RHWM Derksen | 15 | 112 | 35 | 59 | 11 | 274 | |
| T. Ziglioli | 5 | 50 | 33 | 118 | 7 | 252 | |
| José Miguel Couselo | 14 | 115 | 18 | 74 | 13 | 323 | |
| Viviani Pessôa | 28 | 111 | 18 | 212 | 8 | 295 | |
| Gayatri Mittal | 21 | 84 | 13 | 77 | 11 | 327 | |
| I. LUTFI VURAL | 18 | 46 | 41 | 80 | 8 | 320 | |
| Chiara Biasini Rebaioli | 24 | 34 | 29 | 95 | 7 | 313 |
All Works
Loading papers...